Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering
- 1 November 2002
- journal article
- Published by Elsevier BV in Kidney International
- Vol. 62 (5), 1611-1619
- https://doi.org/10.1046/j.1523-1755.2002.00601.x
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- HMG CoA Reductase Inhibitors Reduce Plasminogen Activator Inhibitor-1 Expression by Human Vascular Smooth Muscle and Endothelial CellsArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patientsKidney International, 1999
- Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cellsJournal of the American Society of Nephrology, 1998
- Direct vascular effects of HMG-CoA reductase inhibitorsAtherosclerosis, 1998
- Fibrinolysis in human peritoneum during operationSurgery, 1996
- The discovery and development of HMG-CoA reductase inhibitors.Journal of Lipid Research, 1992
- Effect of Lovastatin on Suppression and Regression of Atherosclerosis in Lipid-Fed RabbitsJournal of Cardiovascular Pharmacology, 1992
- Peritoneal fibrinolytic activity and intra-abdominal adhesionsThe Lancet, 1990
- Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cellsBlood, 1990
- Lovastatin Ameliorates the Development of Glomerulosclerosis and Uremia in Experimental Nephrotic SyndromeAmerican Journal of Kidney Diseases, 1990